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Abstract 
Background: Metastasis directed treatment (MDT) is increasingly performed with the attempt to improve outcome in 
non-small cell lung cancer (NSCLC) patients receiving targeted- or immunotherapy (TT/IT). This study aimed to assess 
the safety and efficacy of metastasis directed stereotactic radiotherapy (SRT) concurrent to TT/IT in NSCLC patients.
Methods: A retrospective multicenter cohort of stage IV NSCLC patients treated with TT/IT and concurrent 
(≤ 30 days) MDT was established. 56% and 44% of patients were treated for oligoprogressive disease (OPD) or poly-
progressive disease (PPD) under TT/IT, polyprogressive respectively. Survival was analyzed using Kaplan–Meier and log 
rank testing. Toxicity was scored using CTCAE v4.03 criteria. Predictive factors for overall survival (OS), progression free 
survival (PFS) and time to therapy switch (TTS) were analyzed with uni- and multivariate analysis.
Results: MDT of 192 lesions in 108 patients was performed between 07/2009 and 05/2018. Concurrent TT/IT con-
sisted of EGFR/ALK-inhibitors (60%), immune checkpoint inhibitors (31%), VEGF-antibodies (8%) and PARP-inhibitors 
(1%). 2y-OS was 51% for OPD and 25% for PPD. After 1 year, 58% of OPD and 39% of PPD patients remained on the 
same TT/IT. Second progression after MDT was oligometastatic (≤ 5 lesions) in 59% of patients. Severe acute and 
late toxicity was observed in 5.5% and 1.9% of patients. In multivariate analysis, OS was influenced by the clinical 
metastatic status (p = 0.002, HR 2.03, 95% CI 1.30–3.17). PFS was better in patients receiving their first line of systemic 
treatment (p = 0.033, HR 1.7, 95% CI 1.05–2.77) and with only one metastases-affected organ (p = 0.023, HR 2.04, 95% 
CI 1.10–3.79). TTS was 6 months longer in patients with one metastases-affected organ (p = 0.031, HR 2.53, 95% CI 
1.09–5.89). Death was never therapy-related.
Conclusions: Metastases-directed SRT in NSCLC patients can be safely performed concurrent to TT/IT with a low 
risk of severe toxicity. To find the ideal sequence of the available multidisciplinary treatment options for NSCLC and 
determine what patients will benefit most, a further evaluated in a broader context within prospective clinical trials is 
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Introduction
The development of targeted-, and immunotherapy 
(TT/IT) has improved the prognosis of stage IV non-
small cell lung cancer (NSCLC) significantly. However, 
due to the development of resistance, most patients will 
eventually develop progressive disease. Since stereotac-
tic radiotherapy (SRT) has emerged as a safe and locally 
effective modality for treatment of oligometastases, its 
use as part of the multimodality treatment in this situ-
ation is increasing [1], as radical local radiotherapy 
of persistent or progressive (oligo-) metastases could 
improve outcome [2–6].
Three randomized trials have shown that addition of 
a localized metastases-directed treatment (MDT) to 
systemic therapy improved progression free survival 
(PFS) as well as overall survival in NSCLC patients with 
oligometastatic disease [7–9]. However, the definition 
of oligometastatic disease varies in literature, while 
research on the identification of a biological oligometa-
static state is ongoing [10]. This becomes obvious in a 
systematic review on oligometastatic NSCLC patients, 
where a variation of 5-year OS between 8.3% and 86% 
was observed [11]. The subcategorization of (oligo-)
metastatic patients remains a challenge, but is impor-
tant as the value of local treatments varies between 
these patients [3, 12].
Besides oligometastatic disease, SRT might also play 
a role as “salvage” treatment in the management of 
patients who have (oligo-)progressive metastatic dis-
ease while under TT/IT [12]. Once a stable oncologi-
cal status is achieved under systematic therapy and no 
severe side effects develop, a patient preferably contin-
ues this drug for as long as possible, assuming that the 
further lines of systematic treatment are characterized 
by a worse therapeutic ratio. Unfortunately, intrinsic 
or acquired resistance to systematic drugs develops in 
nearly all patients [13]. Here, MDT could possibly pre-
vent or delay the switch of systematic therapy by radical 
local treatment of all progressive metastatic sites. This 
study aimed to evaluate efficacy and safety of metas-
tasis directed SRT (MDT) in NSCLC patients who are 
progressive under immuno- or targeted therapy.
Materials and methods
A retrospective international multicenter registry study 
was established by the German Society for Radiation 
Oncology (DEGRO) working group for radiosurgery 
and stereotactic radiotherapy to collect data on stage 
IV patients receiving SRT with concurrent targeted- 
or immunotherapy (TOaSTT study). The study was 
approved by the ethics committees at all participat-
ing sites (BASEC-Nr. 2016–01807). For this study, all 
patients with NSCLC were evaluated. Patients were 
treated with SRT between 07/2009 and 05/2018. Inclu-
sion criteria were: ≥ 18 years of age, diagnosis of stage 
IV synchronous or metachronous metastatic disease, 
histological confirmation of NSCLC, SRT of any cranial 
or extracranial local recurrence or metastasis, treated 
concurrently (≤ 30 days) with any type of following sys-
temic treatments: antibodies, tyrosine kinase inhibitors 
and/or immune-checkpoint inhibitors. Cranial SRT 
was defined as delivery of up to 5 fractions, or one frac-
tion with a minimum of 16 Gy. Stereotactic body radio-
therapy (SBRT) was defined as delivery of ≤ 10 fractions 
with a minimum total dose of 50 Gy (2 Gy equivalent, 
α/β of 10 Gy; the α/β-ratio of 10 represents the intrinsic 
radiosensitivity of NSCLC metastases [14]).
To further evaluate clinical scenarios in which MDT is 
currently often performed, the group of oligoprogressive 
disease patients (OPD, ≤ 5 metastases) and polyprogres-
sive disease patients (PPD, > 5 metastases) was sub-ana-
lyzed. The OPD cohort consisted of patients where MDT 
of either all metastases or all oligoprogressive metasta-
ses was performed; the PPD cohort was characterized 
by patients, where polyprogressive disease was observed 
and only dominant lesions were treated with MDT, 
according to local interdisciplinary decision. Endpoints 
were overall survival (OS), time to therapy switch (TTS), 
progression free survival (PFS), local metastases control 
(LC), and toxicity. OS was defined as time of SRT to time 
of death, living patients were censored at the date of last 
follow-up. PFS and LC were defined as time of SRT to 
time of progression, which was determined by PET-CT/
MRI, MRI, CT, ultrasound or X-ray imaging. PFS and 
LC were evaluated by censoring patients at their most 
recent imaging. TTS was defined as time of MDT to time 
of start of a new systemic therapy. Acute severe toxicity 
(grade ≥ 3 events, < 3 months after SRT) probably caused 
by MDT was analyzed using the Common Terminology 
needed continuation of TT/IT beyond progression combined with MDT for progressive lesions appears promising but 
requires prospective evaluation.
Trial registration: retrospectively registered
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Criteria for Adverse Events (CTCAE) v4.03. Late severe 
(grade ≥ 3 events) toxicity was evaluated in patients with 
a follow-up of ≥ 3 months.
Descriptive statistical analysis was performed with 
SPSS v25.0 statistic software package (IBM Corp., 
Armonk, NY, USA). Kaplan–Meier survival curves with 
log-rank analysis for comparison of subgroups was used 
to evaluate OS, PFS, and TTS. The Fisher`s exact and 
Chi-square test was used to compare differences between 
two independent groups. Univariate and backward multi-
variate Cox regression analysis was performed to identify 
independent variables for OS, PFS and TTS. A p-value of 
less than 0.05 was deemed statistical significant.
Results
Patient characteristics
Data of 108 patients from 16 participating centers was 
included. Baseline patient, tumor and treatment char-
acteristics are summarized in Table  1. Median patient 
age was 63 (range 33–80) years, 90% of patients had 
an ECOG performance score of ≤ 1, 41% had minimal 
co-morbidities (age-adjusted Charlson Comorbidity 
Index ≤ 3). The most frequent histological NSCLC sub-
type was adenocarcinoma (80%). Multiorgan metastatic 
disease was present in 71% of patients, with a median of 
2 (range 1–7) involved organs per patient. Reported rea-
sons for MDT in PPD patients were palliation of symp-
toms (26%), prevention of future complications (79%), 
attempt to extend treatment with current systemic ther-
apy (11%) and to induce a possible immunomodulation 
effect (9%).
Targeted therapy/immunotherapy
Overall, 56% of patients received first line systemic ther-
apy, while 44% were under second-line therapy or more 
(Table 1). Systemic therapy concurrent to MDT consisted 
of EGFR/ALK-inhibitors (60%), immune checkpoint 
inhibitors (31%), VEGF-antibodies (8%) and PARP-inhib-
itors (1%). In 10% of patients, these were combined with 
chemotherapy. Sixty-seven percent of patient started 
TT/IT before MDT, with a median of 269  days (range 
1–180 days), 8% started IT/TT at the same time of SRT 
and 25% started IT/TT a median of 14 days (range 1–30) 
after SRT. Overall, in 28% of patients their systemic ther-
apy was paused during MDT with a median of 10 (range 
2–42) days. Targeted therapy was paused in 35% of the 
patients, for a median of 3 days before and 3 days after 
MDT (range 1–21  days). Immune checkpoint inhibitors 
were paused in 15% of patients, for a median of 7  days 
before and after MDT (range 1–19  days). Bevacizumab 
was paused in 20% of patients for a median of 14  days 
before up to 14 days after MDT (range 7–21 days). The 
decision to pausing TT/IT as well as the length of the 
Table 1 Patient characteristics of  all 108 NSCLC patients 
treated with SRT concurrent to TT/IT
ADC adenocarcinoma, LCNEC  large cell neuroendocrine carcinoma, SqCC 
squamous cell carcinoma
N (%), median (range)
All patients (n = 108)
Age (years) 63 (33–80)
Histology subtype
 ADC 80 (74)
 LCNEC 3 (3)
 SqCC 6 (6)
 Adenosquamous 3 (3)
 Unknown 16 (15)
Synchronous metastatic disease
 Yes 81 (75)
 No 27 (25)
Ligand expression/driver mutation
 EGFR 49 (45)
 ALK 16 (15)
 ROS1 2 (2)
 PD-L1 5 (5)
 No 30 (28)
 Unknown 5 (5)
Previous systemic treatment lines 1 (1–5)
Present metastases
  ≤ 5 53 (49)
  > 5 55 (51)
Involved organs 2 (1–7)
Status of primary tumor
 Controlled 75 (69)
 Progressive 26 (24)
 Unknown 7 (7)
SRT treated lesions
 Brain 144 (75)
 Lymph nodes 3 (2)
 Lung 18 (9)
 Liver 6 (3)
 Adrenal gland 3 (2)
 Bone 17 (9)
 Soft tissue 1 (0.5)
SRT treated lesions per patient
 Cranial 1 (1–5)
 Extracranial 1 (1–3)
Type of systemic therapy
 EGFR/ALK-inhibitor 65 (60)
 PD-1/PD-L1-inhibitor 33 (31)
 Anti-VEGF-antibody 9 (8)
 PARP-inhibitor 1 (1)
Prescribed  BED10 (Gy)
 Cranial 75 (26.6–113.9)
 Extracranial 95.3 (53.1–180)
Total GTV volume (cc)
 Cranial 1.2 (0.04–15.3)
 Extracranial 8.4 (0.5–86.1)
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TT/IT interruption during SRT was at the discretion of 
the participating center.
Stereotactic radiotherapy
In total, 192 lesions were irradiated. Brain metastases 
were the most frequent location (68%), with a median 
number of 1 (range 1–5) brain metastasis treated per 
patient. Median total tumor volume of brain metastases 
was 1.2 cc (range 0.04–15.3). Median prescribed dose for 
brain metastases was 20 Gy in 1 fraction  (BED10 = 75 Gy). 
SBRT was performed in 32% of patients, PPD patients 
received SBRT less often compared to OPD patients (21% 
vs. 41% respectively). A median of 1 (range 1–3) extracra-
nial metastases were treated simultaneously per patient. 
Extracranial metastases were treated with a median dose 
of 95.3  Gy  (BED10) in median 3 fractions (range 1–5). 
Median planning targed volume of SBRT was 8.37  cc 
(range 0.54–86.10 cc).
Efficacy and factors influencing survival
Median follow-up was 18.7 (range 1–102) months. 
Median OS was 18.1 months, 2 year OS was 39% (Fig. 1). 
Cause of death was tumor-related in 85% and never 
therapy-related. There was no significant difference in 
OS between patients with- or without brain metasta-
ses (p = 0.181). There was also no significant difference 
in OS between patients receiving IT, TT, AAT or PARPi 
(p = 0.765). In univariate analysis, metastatic status (OPD 
vs. PPD) and number of affected organs were significant 
predictors of OS (Table 2). In multivariate analysis, meta-
static status remained the only independent factor pre-
dicting OS (p = 0.002, HR 2.03 (95% CI; 1.3–3.17). Local 
control after SRT was 84% after 2 years, there was no dif-
ference between OPD and PPD. Overall, median PFS was 
8.7  months. In OPD, this was median 10.4  months and 
7.4 months for PPD patients, or 25% and 8% after 2 years, 
respectively (Fig. 1). In the univariate analysis, metastatic 
status, previous lines of systemic therapy and affected 
organs were significant predictors of PFS. In multivariate 
analysis, the number of previous lines of systemic ther-
apy [p = 0.033, HR 1.7 (95%CI 1.05–2.77)] and number 
of affected organs (p = 0.023, HR 2.04 (95% CI 1.10–3.79) 
remained independent factors predicting PFS (Table 2).
Patterns of disease progression
In case of progression, only one organ was affected 
(range 1–4) in 69% of OPD patients and 36% of PPD 
patients. These recurrences were oligometastatic (≤ 5 
new lesions) in 59% of OPD patients, with no differ-
ence between concurrent systemic therapy (p = 0.765). 
Forty-three percent of patients that developed a new 
oligoprogression received a second course of MDT. 
Other local therapies consisted of surgery in 2 patients 
Fig. 1  a Overall survival of metastatic NSCLC patients 
receiving metastasis directed therapy (MDT) concurrent to 
targeted- or immunotherapy (TT/IT). b Progression free survival 
(PFS) of oligoprogressive disease (OPD) NSCLC patients receiving 
MDT concurrent to targeted- or immunotherapy (TT/IT). c Time 
to systemic therapy change (TTS) after MDT in in NSCLC patients 
receiving concurrent SRT and TT/IT. Blue line = OPD patients where 
a MDT of all present metastases (≤ 5 metastases) was performed. 
Yellow line = OPD patients where MDT of all progressive lesions was 
performed and all other metastases are controlled by TT/IT
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and conventionally fractionated radiotherapy in 5 
patients.
After one year, 58% of OPD patients and 39% of 
PPD patients were receiving the same systemic ther-
apy as at the time of MDT. The median TTS was 
14  months (range 5.7–22.3  months) for OPD patients 
and 8  months for PPD patients. There was no signifi-
cant difference between administered systemic therapy 
(p = 0.220). In patients where systemic treatment was 
switched, the next line of treatment was usually a new 
targeted therapy in OPD patients (68%) and chemo-
therapy in PPD patients (52%) (Fig. 2). Patients receiv-
ing IT who had progressive disease after SRT switched 
to another IT (60%) or chemotherapy (33%), patients 
receiving TT who developed progressive disease after 
SRT most commonly switched to another TT (65%) 
(Fig. 2).
Toxicity
Acute severe (≥ grade 3, < 30 days) toxicity likely caused 
or worsened by MDT was observed in 6 patients (5.5%), 
consisting of 7 grade 3 toxicities and 1 grade 4 toxic-
ity (Table  3). Late severe toxicity (≥ grade 3, ≥ 30  days) 
was observed in 2 patients (1.9%); one patient with two 
3 grade toxicities and 1 grade 4 toxicity, and one patient 
with grade 3 weight loss. Most severe toxicities occurred 
after SRT of brain metastases and in two cases after 
SBRT of lung metastases. All severe toxicities occurred in 
patients receiving immune checkpoint inhibition, VEGF-
antibody or EGFR-inhibitors. There was no clear pattern 
of occurrence of severe toxicity observed (Table  3). No 
grade 5 toxicity occurred.
Discussion
This analysis of stage IV NSCLC patients receiving 
MDT for progressive or persistent metastases under 
targeted-, or immunotherapy showed survival rates in 
Table 2 Uni- and multivariate Cox regression analysis
p < 0.05 is significant
HR  hazard ratio, CI confidence interval, TT targeted therapy, IT immunotherapy, AAT antiangiogenic therapy, PARPi  PARP-inhibitor
Variables OS PFS TTS
Univariate Multivariate Univariate Multivariate Univariate Multivariate
p value p value HR (95% CI) p value p value HR (95% CI) p value p value HR (95% CI)
Cinical metastatic status 
(OPD, palliative intent)
0.006 0.002 2.03 (1.30–3.17) 0.002 0.334 0.053 0.938 1.0 (0.56–1.81)




0.802 – – 0.895 0.653
Previous lines of systemic 
treatment (1 vs. > 1)
0.166 0.109 – 0.048 0.033 1.7 (1.05–2.77) 0.093 0.152 1.57 (0.84–2.92)
Metastatic burden (1, 2–5, 
6–10, > 10)
0.461 – – 0.062 0.759 0.051 0.686 1.10 (0.741.64)
Affected organs (1 vs. > 1) 0.03 0.633 – 0.004 0.023 2.04 (1.10–3.79) 0.026 0.031 2.53 (1.09–5.89)
Location of metastases (cra-
nial vs. extracranial)
0.201 0.827 – 0.155 0.757 0.48
Histology subtype (SqCC, 
ADC, LCNEC, adenosqua-
mous, unknown)
0.952 – – 0.554 0.447
Gene mutation (yes vs. no) 0.834 – – 0.992 0.696
Status of primary tumor 
(controlled vs. progressive)
0.973 – – 0.701 0.824
Targeted therapy (IT, TT, AAT) 0.855 – – 0.424 0.64
SRT location (cranial, extrac-
ranial, both)
0.25 – – 0.149 0.571 0.767
Number of SRT treated 
metastases (1–5)
0.642 – – 0.993 0.509
Start targeted therapy 
(before, during, after SRT)
0.239 – – 0.436 0.299
Targeted therapy paused 
during SRT (yes vs no)
0.645 – – 0.734 0.104 0.393 1.32 (0.75–2.34)
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the OPD group that appear promising compared to lit-
erature on patients receiving TT/IT alone [15–17]. The 
concept of targeting OPD while continuing systemic 
therapy beyond progression is increasingly performed 
[18, 19]. This is based on the observation that (1) fur-
ther lines of systematic treatment are characterized by a 
worse therapeutic effect, (2) MDT obtains good results 
with limited toxicity in the primary oligometastatic 
situation [7–9], and (3) whole genomic sequencing 
studies showing that through parallel evolution, sub-
populations of metastatic clones are capable to metas-
tasize themselves [20]. This may indicate that MDT of 
these lesions could possibly improve prognosis. Litera-
ture on the concept of MDT for OPD is still limited and 
includes, next to small retrospective studies [2–6], a 
phase II study, which showed that MDT of ≤ 6 progres-
sive metastases in platinum-refractory NSCLC patients 
who received erlotinib resulted in a better PFS and OS 
than would be expected in patients receiving TT alone 
[21]. In all available studies, metastatic patients in vary-
ing phases of their treatment were included, which 
increases the difficulty to interpret their results and 
transfer the data to clinical practice. Furthermore, the 
increasing use of immunotherapy in this population has 
so far not been taken into account. Our study therefore 
analyzes real-life data of the efficacy and safety of MDT 
performed in metastatic NSCLC patients progressive 
under targeted-, as well as immunotherapy.
MDT resulted in a good OS in OPD patients, and 
allowed continuation of systemic therapy within the first 
year for many patients. The effect of MDT in the patient 
group treated with palliative intent was less pronounced 
in terms of OS and PFS. However, these patients were 
most frequently treated with SRT for brain metastases. 
Fig. 2 Flow chart of systemic therapy switch following SRT
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Some TT/IT are characterized by good penetration of 
the blood–brain barrier; however, upfront MDT of cer-
ebral metastases might improve patient outcome and 
quality of life [22–25].
When a new progression occurred after MDT, this was 
often again OPD and a repeat-irradiation was performed 
in most of these patients. The effectiveness of repeat-
irradiations has been previously published for prostate 
cancer recurrences and treatment of brain metastases, 
generally resulting in an excellent local control with lim-
ited toxicity [22]. In our multivariate analysis, it was 
shown that the number of lines of systemic therapy influ-
enced PFS. This reflects that the reducing efficacy of sub-
sequent lines of therapy drives distant progression and 
appears to be more important than metastatic burden 
at time of MDT. Repeat-MDT instead of therapy-switch 
may therefore play an increasingly important role. How-
ever, experiences of repeat-irradiation remain limited 
and further studies need to investigate carefully the con-
cept of repeat local treatment.
Although the concept of MDT for OPD under TT/IT 
is practiced with increasing frequency, several uncertain-
ties remain. First of all, with the currently limited knowl-
edge on the molecular background of resistant clones in 
NSCLC, it is not known whether preferably all metasta-
ses or just selected progressive metastases should be tar-
geted, and what the threshold of the number and volume 
of targeted metastases should be [26]. Current decision-
making is based on imaging and clinical criteria [11, 27], 
but studies on the biological status of metastatic NSCLC 
is urgently needed, including integration of liquid biopsy 
for staging and response assessment. Secondly, the tim-
ing of MDT currently remains a clinical decision, usually 
based on CT or PET-images. However, progression under 
TT/IT can be very slow, or after immunotherapy, a pseu-
doprogression could be observed. Thirdly, there might 
be different strategies in combining systemic therapies 
with MDT, as the effects of concurrent treatment may be 
diverse. For example, combining immunotherapy with 
MDT could possibly strengthen the antitumor immune 
response [28], whereas abscopal effects of radiotherapy 
are exceedingly unlikely in patients not receiving immu-
notherapy [26].
A limitation of this study is its retrospective nature 
which, however, is a way of a meaningful evaluation of 
a quickly changing clinical field and associated limita-
tions in standardization of reporting of factors, such 
as toxicity and local control. Since there is a known 
risk of underreporting low grade toxicity in retrospec-
tive studies, only high grade toxicity was registered 
[29]. Furthermore, as all patients received a combined 
modality treatment, our study does not allow to eval-
uate the influence of the continued TT/IT alone on 
outcome. It may be possible, that patients with less 
metastatic sites have had a better prognosis irrespec-
tive of MDT. Especially under immunotherapy, residual 
sites potentially could remain stable for a longer time. 
However, for patients receiving targeted therapy a 
Table 3 Observed infield acute and late severe (≥ grade 3) toxicity, graded by use of CTCAE v4.03














 1 Headache 3 Brain 3 24 Gy/1fx 100% 
Isodose)
Nivolumab 8 days after SRT –
 2 Headache 3 Brain 1 20 Gy/1fx (80% 
Isodose)
Bevacizumab 365 days before 
SRT
No
 3 Headache 3 Brain 2 20 Gy/1fx (80% 
Isodose)




 4 Headache 4 Brain 3 20 Gy/1fx (80% 
Isodose)
Nivolumab 11 days after SRT –
Nausea 3
 5 Dyspnea 3 Lung 1 7 Gy/5fx (65% 
Isodose)
Gefitinib 503 days before 
SRT
No
 6 Thromboembolic 
event
3 Brain 1 20 Gy/1fx (80% 
Isodose)




 7 Radionecrosis 3 Brain 5 20 Gy/1fx (80% 
Isodose)





 8 Weight loss 3 Lung 1 7 Gy/5fx (65% 
Isodose)
Erlotinib 575 days before 
SRT
4 days
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further progress of residual sites can be expected after 
several months. A first study comparing targeted ther-
apy as monotherapy to a combined modality therapy 
with SRT indicated a benefit of combined therapy com-
pared to targeted drugs alone [30] and will be further 
investigated in the randomized HALT (NCT03256981) 
and STOP-NSCLC NCT02756793 trials. Another limi-
tation is the combined analysis of patients treated with 
IT/TT in one study population. This was done because 
the intention of MDT was similar irrespective of the 
systemic therapy, namely ablation of (oligo-) progres-
sive metastases while the otherwise effective systemic 
therapy is continued.
In conclusion, metastases-directed SRT in NSCLC 
patients can be safely performed concurrent to TT/
IT with a low risk of severe toxicity. To find the ideal 
sequence of the available multidisciplinary treatment 
options for NSCLC and determine what patients will 
benefit most, a further evaluated in a broader context 
within prospective clinical trials is needed continuation 
of TT/IT beyond progression combined with MDT for 
progressive lesions appears promising but requires pro-
spective evaluation.
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